close

Fenwick Represents Sutro Biopharma in its $85 Million Initial Public Offering

October 04, 2018

​​Fenwick & West represented Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF™, to create a broad variety of protein therapeutics for cancer and autoimmune disorders, in its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 850,050 shares of common stock.

Cowen and Piper Jaffray acted as joint book-running mangers for the offering. JMP Securities and Wedbush PacGrow acted as co-managers.

The Fenwick transaction team included corporate lawyers Effie Toshav, Rob Freedman, Amanda Rose, Jennifer Hitchcock, Amy Zhang and Derrick Chapman; and executive compensation and employee benefits lawyers Scott Spector, Elizabeth Gartland and Sarah Ghulamhussain.